Yes. But the share price in 2021 was based on the Covid19 Neutralizing Antibody test. If the FDA would have approved that test, AXIM may have deserved that value.
According to Mr Huemoeller these DED tests can be a big deal as well even before CLIA Waivers.
But if the CLIA Waivers are approved for DED tests, AXIM has a chance for a really big return on investment over time.
News 
Market Data 
Discover 
